The level of serum duplex-linear DNA (dlDNA) increases markedly with liver disease progression and development of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV) ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
– Oral presentation highlights significant reduction in HBV DNA integration and other clinically-relevant biomarkers from the EBT-107 therapeutic candidate in preclinical mouse models WATERTOWN, Mass.
First CTA authorization marks nChroma's transition to a clinical-stage company; first patient dosing in Phase 1/2 trial planned for early 2026 Preclinical studies demonstrated CRMA-1001 delivers ...
When Brian Cosgrove, PhD, Principal Scientist at Tune Therapeutics, was thinking of what to go after with epigenetic editing, generating first-in-class viral therapeutics—in particular, the hepatitis ...
Aligos Therapeutics is a clinical-stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases. The company is dedicated to educating ...
Atomic force microscopy images show hepatitis B DNA in its natural state (left) and a zoomed-in look at how it wraps around human histones during an infection (right). Disrupting this process in an ...
Patients with chronic hepatitis B virus (HBV) infection in the immune-tolerant phase may still experience hepatic inflammation and disease progression, and could benefit from early antiviral treatment ...
-- Two oral presentations and one poster will feature new data from the Company’s hepatitis B/hepatitis D entry inhibitor, capsid assembly modulator ABI-4334, and interferon-alpha receptor agonist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback